December 1, 2016 - By Richard Conner · 0 Comments
The stock of Dermira Incorporated (NASDAQ:DERM) registered an increase of 1.63% in short interest. DERM’s total short interest was 2.16 million shares in December as published by FINRA. Its up 1.63% from 2.12 million shares, reported previously. With 117,200 shares average volume, it will take short sellers 18 days to cover their DERM’s short positions. The short interest to Dermira Incorporated’s float is 8.64%. The stock closed at $31.98 during the last session. It is down 25.17% since April 28, 2016 and is uptrending. It has outperformed by 19.24% the S&P500.
Dermira, Inc. is a biopharmaceutical company. The company has a market cap of $1.12 billion. The Firm is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. It currently has negative earnings. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia , DRM04 and DRM01.
Insitutional Activity: The institutional sentiment decreased to 1.52 in 2016 Q2. Its down 1.26, from 2.78 in 2016Q1. The ratio is negative, as 11 funds sold all Dermira Inc shares owned while 21 reduced positions. 35 funds bought stakes while 54 increased positions. They now own 29.11 million shares or 30.57% more from 22.30 million shares in 2016Q1.
Perceptive Advsr Ltd Co has 462,000 shares for 0.94% of their US portfolio. Ubs Oconnor Ltd Llc owns 52,449 shares or 0% of their US portfolio. California Pub Employees Retirement last reported 14,200 shares in the company. Alliancebernstein Limited Partnership accumulated 37,400 shares or 0% of the stock. Sabby Mgmt Limited Liability Com has 26,693 shares for 0.04% of their US portfolio. Dafna Cap Ltd last reported 4.49% of its portfolio in the stock. Great Point Prns Limited Liability Co accumulated 6.7% or 800,000 shares. The California-based Franklin Resources has invested 0.01% in Dermira Inc (NASDAQ:DERM). Balyasny Asset Management Lc has 0.12% invested in the company for 612,031 shares. The United Kingdom-based Marshall Wace Llp has invested 0.01% in Dermira Inc (NASDAQ:DERM). Millennium Mngmt Ltd Liability Company accumulated 313,886 shares or 0.02% of the stock. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Barclays Public Limited reported 45,843 shares or 0% of all its holdings. Fmr Ltd Liability Corp last reported 0.02% of its portfolio in the stock. Brown Brothers Harriman & has 0% invested in the company for 135 shares.
Insider Transactions: Since June 13, 2016, the stock had 0 insider buys, and 23 selling transactions for $4.31 million net activity. Another trade for 11,000 shares valued at $325,770 was sold by WIGGANS THOMAS G. BAUER EUGENE A also sold $82,950 worth of Dermira Inc (NASDAQ:DERM) on Monday, August 1. 1,303 shares were sold by Griffith Christopher M., worth $41,370 on Monday, August 15. $16,825 worth of Dermira Inc (NASDAQ:DERM) shares were sold by RINGO WILLIAM R. Another trade for 10,000 shares valued at $325,300 was made by GUGGENHIME ANDREW on Monday, September 12.
Out of 4 analysts covering Dermira Inc (NASDAQ:DERM), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dermira Inc has been the topic of 8 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, December 18 by Citigroup. The stock has “Outperform” rating given by Cowen & Co on Wednesday, August 19. The firm has “Buy” rating by Citigroup given on Wednesday, March 16. The stock of Dermira Inc (NASDAQ:DERM) has “Buy” rating given on Friday, January 8 by Needham. Needham maintained the shares of DERM in a report on Wednesday, May 11 with “Buy” rating.
Dermira, Inc., incorporated on August 18, 2010, is a biopharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), in Phase III development for the treatment of moderate-to-severe chronic plaque psoriasis; DRM04, in Phase III development for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating, and DRM01, in Phase IIb development for the treatment of acne vulgaris, or acne. The Firm is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as psoriasis, hyperhidrosis and acne.
Another recent and important Dermira Inc (NASDAQ:DERM) news was published by Marketwatch.com which published an article titled: “Dermira Inc. NASDAQ: DERM” on October 03, 2014.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner